Elucis

Elucis Therapeutics is a biotechnology company pioneering the discovery and development of cancer vaccines targeting the "dark matter" of the human genome. The company utilizes a proprietary discovery platform to identify non-canonical antigens—sequences that do not code for traditional proteins but are expressed specifically in tumor cells. By targeting these novel antigens, Elucis aims to create immunotherapies with broader applicability and higher specificity than traditional neoantigen approaches. The company is currently in the pre-clinical stage, advancing a pipeline of therapeutic vaccines designed to treat various solid tumors. Their mission is to transform oncology treatment through highly precise, off-the-shelf and personalized vaccine strategies.